Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

83.05USD
17 Jun 2019
Change (% chg)

$0.27 (+0.33%)
Prev Close
$82.78
Open
$82.88
Day's High
$83.06
Day's Low
$82.54
Volume
276,520
Avg. Vol
3,204,047
52-wk High
$84.26
52-wk Low
$59.81

Latest Key Developments (Source: Significant Developments)

IBM, KPMG, Merck And Walmart in blockchain collaboration with FDA
Thursday, 13 Jun 2019 08:05am EDT 

June 13 (Reuters) - Walmart Inc ::IBM, KPMG, MERCK AND WALMART TO COLLABORATE AS PART OF FDA'S PROGRAM TO EVALUATE THE USE OF BLOCKCHAIN TO PROTECT PHARMACEUTICAL PRODUCT INTEGRITY.IBM - PILOT PROJECT IS SCHEDULED TO BE COMPLETED IN Q4 OF 2019.IBM - BLOCKCHAIN MAY BE INTEGRATED WITH EXISTING SUPPLY CHAIN AND TRACEABILITY SYSTEMS.IBM - PROGRAM IS TO ASSIST DRUG SUPPLY CHAIN STAKEHOLDERS IN DEVELOPING A SYSTEM THAT WILL IDENTIFY, TRACE CERTAIN PRESCRIPTION DRUGS DISTRIBUTED IN U.S..  Full Article

Merck Says Keytruda Showed Improved Overall Survival In Head & Neck Cancer Trial
Friday, 31 May 2019 06:45am EDT 

May 31 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DEMONSTRATES IMPROVED OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AT FINAL ANALYSIS OF PIVOTAL PHASE 3 KEYNOTE-048 TRIAL.MERCK & CO - FOR DUAL PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL, STATISTICAL SIGNIFICANCE NOT ACHIEVED FOR KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY IN CPS≥20 POPULATION VERSUS EXTREME REGIMEN.MERCK & CO - FOR CPS ≥1 POPULATION KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 35% IN THESE PATIENTS, WITH SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.MERCK & CO - KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 40% IN PATIENTS WHOSE TUMORS EXPRESSED PD-L1 WITH CPS≥20, SHOWING SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.  Full Article

Zymeworks Earns Milestone Payment In Merck Collaboration
Wednesday, 29 May 2019 06:45am EDT 

May 29 (Reuters) - Zymeworks Inc ::ZYMEWORKS EARNS MILESTONE PAYMENT IN MERCK COLLABORATION.ZYMEWORKS - UNDER TERMS, CO GRANTED MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, DEVELOP & COMMERCIALIZE CERTAIN BISPECIFIC THERAPEUTIC CANDIDATES.ZYMEWORKS - UNDER TERMS, CO IS ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON PRODUCT SALES.ZYMEWORKS INC - WILL RECEIVE US$2.0 MILLION IN CONNECTION WITH MERCK'S COMPLETION OF A LATE-STAGE PRECLINICAL STUDY FOR A BISPECIFIC ANTIBODY CANDIDATE.  Full Article

Merck Sets Quarterly Dividend Of $0.55 Per Share
Tuesday, 28 May 2019 04:05pm EDT 

May 28 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.55PER SHARE.  Full Article

Merck To Acquire Peloton Therapeutics For An Upfront Payment Of $1.05 Billion In Cash
Tuesday, 21 May 2019 06:45am EDT 

May 21 (Reuters) - Merck & Co Inc ::MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK & CO INC - MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH.MERCK & CO INC - WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH..MERCK & CO - PELOTON SHAREHOLDERS ELIGIBLE TO RECEIVE FURTHER $1.15 BILLION CONTINGENT UPON SUCCESSFUL ACHIEVEMENT OF FUTURE MILESTONES FOR CERTAIN CANDIDATES.MERCK & CO INC - ACQUISITION INCLUDES NOVEL LATE-STAGE RENAL CELL CARCINOMA CANDIDATE, PT2977.MERCK & CO INC - COMPANIES ANTICIPATE ACQUISITION WILL CLOSE IN Q3 OF 2019.  Full Article

Third Point LLC Dissolves Share Stake In Merck & Co Inc
Wednesday, 15 May 2019 05:20pm EDT 

May 15 (Reuters) - Third Point LLC::THIRD POINT LLC DISSOLVES SHARE STAKE IN MERCK & CO INC.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Moderna Says Merck Has Elected To Conduct A Phase 1 Clinical Trial For mRNA-1172
Wednesday, 8 May 2019 10:35am EDT 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MODERNA INC - MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck Announces Results From Mid-Stage Trial Of Investigational 15-Valent Pneumococcal Conjugate Vaccine
Wednesday, 8 May 2019 09:00am EDT 

May 8 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES RESULTS FROM PHASE 2 TRIAL OF INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) IN INFANTS.MERCK & CO INC - V114 MET PRIMARY ENDPOINT BY DEMONSTRATING NONINFERIORITY TO PCV13 FOR ALL SHARED SEROTYPES, AND AN IMMUNE RESPONSE FOR TWO ADDITIONAL SEROTYPES.MERCK & CO INC - DATA SUPPORT CONTINUED PROGRESSION OF PHASE 3 STUDIES WITH V114.  Full Article

Moderna Inc Entered Into A Fifth Amendment To Collaboration And License Agreement With Merck Sharp & Dohme Corp
Wednesday, 8 May 2019 07:28am EDT 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck’S Belsomra (Suvorexant) C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial
Tuesday, 7 May 2019 06:45am EDT 

May 7 (Reuters) - Merck & Co Inc ::MERCK’S BELSOMRA® (SUVOREXANT) C-IV MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL FOR THE TREATMENT OF INSOMNIA IN PEOPLE WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE DEMENTIA.MERCK & CO INC - DATA TO BE FILED WITH FDA FOR POTENTIAL INCLUSION IN BELSOMRA PRESCRIBING INFORMATION.MERCK & CO INC - ADVERSE EVENTS WERE RECORDED IN 22.5% (N=32/142) OF PATIENTS IN BELSOMRA GROUP AND 16.1% (N=23/143) IN PLACEBO GROUP.MERCK & CO INC -IN TRIAL, BELSOMRA MET ITS PRIMARY AND SECONDARY EFFICACY ENDPOINTS.MERCK & CO INC - ONE PATIENT IN EACH GROUP DISCONTINUED TREATMENT DUE TO AN ADVERSE EVENT.  Full Article

Walmart, Merck in blockchain collaboration with FDA

June 13 IBM Corp, Merck & Co, KPMG and Walmart Inc said on Thursday they will be a part of U.S. Food and Drug Administration's pilot program that will explore using blockchain to identify, track and trace prescription drugs.